Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis

• Egile Nagusiak: Abdolhalim Rajabi (Egilea), Heidar Sharafi (Egilea), Seyed Moayed Alavian (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Prevalence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) in Iran is high. Since 2005, the Iranian government has implemented a harm reduction program to control HCV. We aimed to describe the prevalence of HCV antibody (Ab) in Iranian PWID before and af...